Holen Sie sich die Stockscreener-App
1.65
3.51%
-0.06
Vorhandelsmarkt:
1.70
0.05
+3.03%
Metavia Inc Aktie (MTVA) Neueste Nachrichten
MTVA Technical Analysis & ETF Price Forecast - Intellectia AI
MTVA: DA-1726 and vanoglipol show strong clinical and combination potential, with solid cash runway - TradingView
MTVA: Combination therapies show significant weight loss and metabolic benefits; trials fully funded - TradingView
MetaVia Shareholders Approve Equity Plan and Reverse Split - The Globe and Mail
MetaVia Company Profile & Introduction - Moomoo
H.C. Wainwright Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Get insights into the top gainers and losers of Tuesday's pre-market session. - ChartMill
MetaVia (MTVA) director awarded 17,186 RSUs vesting in 2027 - Stock Titan
MetaVia (MTVA) awards 17,186 stock units to board director - Stock Titan
MetaVia (MTVA) director gets 17,186 RSUs vesting in 2027 - Stock Titan
MetaVia (MTVA) director Jason Groves awarded 17,186 RSUs in equity grant - Stock Titan
MetaVia (MTVA) director Andrew Koven receives 17,186 deferred RSU grant - Stock Titan
MetaVia Inc. (MTVA) director receives 17,186-share restricted stock grant - Stock Titan
According to documents submitted to the U.S. Securities and Exchange Commission, shareholders of MetaVia Inc have approved a reverse stock split plan, with the specific ratio to be determined within the range of 1-for-5 to 1-for-22. - Bitget
MetaVia (NASDAQ: MTVA) investors back reverse split and equity plan changes - Stock Titan
MetaVia presents promising obesity and metabolic data at ADA 2026 - grafa.com
MTVA: All five business proposals, including a reverse stock split, were approved by shareholders - TradingView
MTVA: All five proposals, including director elections and a reverse stock split, were approved - TradingView
MetaVia Presents Promising DA-1726 and Vanoglipel Combination Data for Obesity and Metabolic Disease at ADA 2026 Sessions - Minichart
MetaVia highlights obesity and metabolic pipeline advancements - TipRanks
MetaVia (NASDAQ: MTVA) posts DA-1726 and vanoglipel obesity, MASH data - Stock Titan
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential - Lelezard
MetaVia reports obesity drug data at diabetes conference By Investing.com - Investing.com Canada
MetaVia's DA-1726 shows 9.1% weight loss at Day... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
MetaVia reports obesity drug data at diabetes conference - Investing.com
MTVA Stock Price and Chart — NASDAQ:MTVA - TradingView
MTVA Soars As MetaVia Cardiometabolic Data Heads To ADA 2026 - StocksToTrade
MTVA Soars As MetaVia’s Diabetes Data Triggers Volatile Surge - StocksToTrade
MetaVia (MTVA) Soars On ADA 2026 Cardiometabolic Breakthrough Buzz - timothysykes.com
Hear MetaVia discuss new obesity and metabolic therapies at June 11 webcast - Stock Titan
MetaVia Stock Slips Again Before a Big Obesity-Drug Week - Bez Kabli
Why MetaVia Stock Is Surging On Friday? - MSN
MSN Money - MSN
MetaVia Inc. (MTVA) Sheds Over 8% as Shares Approach Key SupportSynthetic Short - The Legal Advocate
H.C. Wainwright Maintains MetaVia(MTVA.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726 - Yahoo Finance
MetaVia reports phase 1 data for obesity drug DA-1726 - Investing.com UK
Metavia Inc MTVA-Q Earnings - The Globe and Mail
MetaVia highlights promising Phase 1 obesity drug data - TipRanks
MetaVia reports phase 1 data for obesity drug DA-1726 By Investing.com - Investing.com Australia
Meta Presents Phase 1 DA-1726 Data Showing Up to 9.1% Weight Loss and Early Liver Improvements - TradingView
MetaVia (Nasdaq: MTVA) posts Phase 1 DA-1726 obesity and MASH data - Stock Titan
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH - PR Newswire
MTVA Q1 2026 Earnings: EPS Misses Estimates, Shares Tumble 22.86%Guidance vs Actual - The Legal Advocate
MetaVia Inc. (MTVA) Tumbles 22.86% as Selling Pressure Intensifies Below Critical ThresholdTICK Divergence - The Legal Advocate
MTVA Q1 2026 Earnings: EPS Misses Estimates but Stock Surges 34.15%High Estimate Range - thelegaladvocate.com
No Analysis Provided - StocksToTrade
"MetaoraPro announcement.fny"Results on X | Live Posts & Updates - x.com
MTVA Soars As MetaVia Cardiometabolic Data Ignites Speculative Surge - timothysykes.com
Metavia Inc (MTVA-Q) Insider Trade Summaries - The Globe and Mail
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):